Development of a Dual and Selective Small Molecule Inhibitor of EGFR and PI3 Kinase to Treat BRAF Mutant Colorectal Cancer
开发 EGFR 和 PI3 激酶双重选择性小分子抑制剂来治疗 BRAF 突变结直肠癌
基本信息
- 批准号:10377535
- 负责人:
- 金额:$ 42.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-17 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseAdoptedBRAF geneBindingBiologicalCancer ModelCecumCellsClinicalClinical TreatmentClinical TrialsColorectalColorectal CancerDataDevelopmentDiagnosisDiseaseDoseDrug KineticsEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorExhibitsFamily memberFutureGene Expression ProfilingGoalsGrowthHumanImplantIn VitroKRAS2 geneLeadLongevityMEKsMalignant NeoplasmsMediatingMitogen-Activated Protein KinasesModelingMolecularMolecular ProfilingMolecular TargetMusMutationNeoplasm MetastasisOncogenicPTEN genePathway interactionsPatientsPatternPharmacodynamicsPharmacologic SubstancePhosphatidylinositide 3-Kinase InhibitorPhosphotransferasesPreclinical TestingPrognosisPrognostic MarkerRefractoryRegimenReportingScheduleSignal TransductionSignaling MoleculeSpecimenSurvival RateTestingTherapeutic IndexToxic effectTumor Suppressor ProteinsValinebiomarker developmentbiomarker signaturecancer cellcandidate markerclinical developmentcolon cancer patientscolorectal cancer treatmentcomparativecomparative efficacydesigndrug candidateeffective therapyefficacy studyexome sequencingimplantationimprovedimproved outcomein vivoin vivo evaluationinhibitormetastatic colorectalmutantnovelpatient derived xenograft modelpatient prognosispatient subsetsphosphoproteomicspre-clinicalrational designresponders and non-respondersresponsesmall moleculesmall molecule inhibitorsuccesstargeted agenttherapy outcometreatment durationtreatment strategytumortumor progression
项目摘要
Despite the emergence of an increased number of molecular targeted agents, the prognosis for patients with
metastatic colorectal cancer (CRC) remains poor with 5 year survival rates of <10%. Agents targeting epidermal
growth factor receptor (EGFR) have met with limited success in the clinical treatment of CRC and are limited to
treatment of those patients whose tumors do not harbor mutations in KRAS or BRAF. Approximately 10% of
colorectal malignancies are known to possess a BRAF valine 600 (BRAFV⁶⁰⁰) mutation, conferring an extremely
poor prognosis. Reactivation of the MAP kinase pathway by EGFR and the co-occurrence of PIK3A mutations
or loss of expression of the tumor suppressor PTEN serve to render BRAFmt tumors refractory to MEK or BRAF
inhibitor monotherapies. Our central hypothesis is that a dual small molecule inhibitor that potently and
selectively targets only EGFR and PI3KA in combination with an inhibitor of MAP kinase signaling represents a
viable strategy for the treatment of BRAF mutant colorectal cancers. To test this hypothesis, we have designed
small molecules that exhibit potent and selective dual inhibition of EGFR and PIK3A family members. To the
best of our knowledge, the lead compound MTX-211 represents a first in class selective inhibitor of these two
critical oncogenic kinases. We have generated crystallographic evidence confirming that MTX-211 binds to
these two kinases in the manner predicted from its computational design, adopting a flipped binding mode to
selectively and potently inhibit both EGFR and PI3K. Preliminary data have shown a striking increase in lifespan
of mice implanted with patient-derived BRAFmt CRC when treated with the combination of MTX-211 and the MEK
inhibitor trametinib. We now propose to carry out more extensive preclinical testing of MTX-211 in patient derived
xenograft models established from patients diagnosed with BRAFmt CRC to bolster the case for this clinical
development path. Molecular profiling will be carried out to elucidate markers that correlate with inherent
sensitivity as well as the adaptive signaling changes that lead to progression. Additionally, we propose to
maximize durability of response by carrying out comparative efficacy studies of MTX-211 combined with clinically
approved MEK versus RAF inhibitors to inform the design of future clinical trials of this promising drug candidate
for treatment of this recalcitrant disease.
尽管出现了越来越多的分子靶向药物,
转移性结肠直肠癌(CRC)仍然较差,5年存活率<10%。靶向表皮的药剂
生长因子受体(EGFR)在CRC的临床治疗中取得了有限的成功,
治疗那些肿瘤不携带KRAS或BRAF突变的患者。约10%的
已知结直肠恶性肿瘤具有BRAF缬氨酸600(BRAFV缬氨酸)突变,赋予了极高的特异性。
预后不良。EGFR对MAP激酶通路的再激活和PIK 3A突变的共同发生
肿瘤抑制因子PTEN表达的缺失或缺失可使BRAFmt肿瘤对MEK或BRAF不敏感
抑制剂单一疗法。我们的中心假设是一种双重小分子抑制剂,
选择性地仅靶向EGFR和PI 3 KA与MAP激酶信号传导抑制剂的组合代表了一种新的治疗方法,
治疗BRAF突变型结直肠癌的可行策略。为了验证这一假设,我们设计了
这些小分子表现出对EGFR和PIK 3A家族成员的有效和选择性双重抑制。到
据我们所知,先导化合物MTX-211是这两种药物的首选选择性抑制剂
关键的致癌激酶。我们已经产生了晶体学证据,证实MTX-211结合到
这两种激酶以其计算设计预测的方式,采用翻转结合模式,
选择性和有效地抑制EGFR和PI 3 K。初步数据显示,
当用MTX-211和MEK的组合治疗时,
抑制剂曲美替尼。我们现在建议进行更广泛的MTX-211临床前试验,
从诊断为BRAFmt CRC的患者中建立的异种移植模型,以支持本临床研究的病例
将进行分子谱分析以阐明与遗传相关的标记。
敏感性以及导致进展的适应性信号变化。此外,我们建议
通过进行MTX-211与临床药物联合治疗的疗效比较研究,
已批准MEK与RAF抑制剂的比较,为这种有前途的候选药物的未来临床试验设计提供信息
来治疗这种顽固的疾病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Judith S Leopold其他文献
Judith S Leopold的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Judith S Leopold', 18)}}的其他基金
Development of Novel Combination Strategies to Overcome Resistance to KRASG12C Inhibition in Colorectal Cancers
开发新的组合策略来克服结直肠癌对 KRASG12C 抑制的耐药性
- 批准号:
10512415 - 财政年份:2022
- 资助金额:
$ 42.76万 - 项目类别:
Development of Novel Combination Strategies to Overcome Resistance to KRASG12C Inhibition in Colorectal Cancers
开发新的组合策略来克服结直肠癌对 KRASG12C 抑制的耐药性
- 批准号:
10666698 - 财政年份:2022
- 资助金额:
$ 42.76万 - 项目类别:
Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers
开发治疗鳞状头颈癌的新型治疗分子
- 批准号:
10666868 - 财政年份:2022
- 资助金额:
$ 42.76万 - 项目类别:
Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers
开发治疗鳞状头颈癌的新型治疗分子
- 批准号:
10325253 - 财政年份:2021
- 资助金额:
$ 42.76万 - 项目类别:
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
使用一流的双靶向 PI3K/EGFR 抑制剂对抗胰腺癌耐药性
- 批准号:
10197037 - 财政年份:2019
- 资助金额:
$ 42.76万 - 项目类别:
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
使用一流的双靶向 PI3K/EGFR 抑制剂对抗胰腺癌耐药性
- 批准号:
10652462 - 财政年份:2019
- 资助金额:
$ 42.76万 - 项目类别:
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
使用一流的双靶向 PI3K/EGFR 抑制剂对抗胰腺癌耐药性
- 批准号:
10432048 - 财政年份:2019
- 资助金额:
$ 42.76万 - 项目类别:
Development of a Dual and Selective Small Molecule Inhibitor of EGFR and PI3 Kinase to Treat BRAF Mutant Colorectal Cancer
开发 EGFR 和 PI3 激酶双重选择性小分子抑制剂来治疗 BRAF 突变结直肠癌
- 批准号:
9896781 - 财政年份:2018
- 资助金额:
$ 42.76万 - 项目类别:
Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer
开发用于治疗 KRAS 突变结直肠癌的 MTX-211
- 批准号:
9891971 - 财政年份:2017
- 资助金额:
$ 42.76万 - 项目类别:
Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer
开发用于治疗 KRAS 突变结直肠癌的 MTX-211
- 批准号:
9255740 - 财政年份:2017
- 资助金额:
$ 42.76万 - 项目类别:
相似海外基金
How novices write code: discovering best practices and how they can be adopted
新手如何编写代码:发现最佳实践以及如何采用它们
- 批准号:
2315783 - 财政年份:2023
- 资助金额:
$ 42.76万 - 项目类别:
Standard Grant
One or Several Mothers: The Adopted Child as Critical and Clinical Subject
一位或多位母亲:收养的孩子作为关键和临床对象
- 批准号:
2719534 - 财政年份:2022
- 资助金额:
$ 42.76万 - 项目类别:
Studentship
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2633211 - 财政年份:2020
- 资助金额:
$ 42.76万 - 项目类别:
Studentship
A material investigation of the ceramic shards excavated from the Omuro Ninsei kiln site: Production techniques adopted by Nonomura Ninsei.
对大室仁清窑遗址出土的陶瓷碎片进行材质调查:野野村仁清采用的生产技术。
- 批准号:
20K01113 - 财政年份:2020
- 资助金额:
$ 42.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2436895 - 财政年份:2020
- 资助金额:
$ 42.76万 - 项目类别:
Studentship
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2633207 - 财政年份:2020
- 资助金额:
$ 42.76万 - 项目类别:
Studentship
The limits of development: State structural policy, comparing systems adopted in two European mountain regions (1945-1989)
发展的限制:国家结构政策,比较欧洲两个山区采用的制度(1945-1989)
- 批准号:
426559561 - 财政年份:2019
- 资助金额:
$ 42.76万 - 项目类别:
Research Grants
Securing a Sense of Safety for Adopted Children in Middle Childhood
确保被收养儿童的中期安全感
- 批准号:
2236701 - 财政年份:2019
- 资助金额:
$ 42.76万 - 项目类别:
Studentship
A Study on Mutual Funds Adopted for Individual Defined Contribution Pension Plans
个人设定缴存养老金计划采用共同基金的研究
- 批准号:
19K01745 - 财政年份:2019
- 资助金额:
$ 42.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural and functional analyses of a bacterial protein translocation domain that has adopted diverse pathogenic effector functions within host cells
对宿主细胞内采用多种致病效应功能的细菌蛋白易位结构域进行结构和功能分析
- 批准号:
415543446 - 财政年份:2019
- 资助金额:
$ 42.76万 - 项目类别:
Research Fellowships














{{item.name}}会员




